Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	15.85	12.15	10.24	10.07	9.49
Research & Development	33.48	39.38	23.68	19.83	22.98
Total Operating Expenses	49.33	51.52	33.92	29.91	32.48
Operating Income	-49.33	-51.52	-33.92	-29.91	-32.48
Interest Income	6.54	3.6	4.75	1.74	0.01
Interest Expense	-	-0	-0.39	-1.16	-1.2
Other Non-Operating Income (Expense)	-0.03	-0.02	0.47	0.14	-0.29
Total Non-Operating Income (Expense)	6.51	3.58	4.83	0.72	-1.49
Pretax Income	-42.82	-47.94	-29.1	-29.19	-33.96
Provision for Income Taxes	-0.06	-0.03	0.03	0.04	0.02
Net Income	-42.76	-47.91	-29.07	-29.15	-33.94
Net Income to Common	-42.76	-47.91	-29.07	-29.15	-33.94
Shares Outstanding (Basic)	135	102	99	65	23
Shares Outstanding (Diluted)	135	102	99	65	23
Shares Change (YoY)	32.14%	2.97%	53.44%	182.56%	26.48%
EPS (Basic)	-0.32	-0.47	-0.29	-0.45	-1.49
EPS (Diluted)	-0.32	-0.47	-0.29	-0.45	-1.49
Shares Outstanding	128.31	93.6	68.28	59.94	28.51
Free Cash Flow	-42.1	-38.29	-31.85	-28.33	-28.95
Free Cash Flow Per Share	-0.31	-0.38	-0.32	-0.44	-1.27
EBITDA	-49.18	-51.38	-33.8	-29.86	-32.43
EBIT	-49.33	-51.52	-33.92	-29.91	-32.48
Effective Tax Rate	0.15%	0.06%	-0.11%	-0.12%	-0.06%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q